肠道中的血凝素故事
1IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), CS60039, Toulouse, Cedex 03, 31024, France; Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, Ab T2N 4N1, Canada.
Biochimie
|March 23, 2024
概括
血凝素,传统上是血液凝固的,在肠道生理学和病理生理学中起着关键作用. 它的受体在肠道中广泛存在,影响屏障,免疫和运动功能,建议新的治疗点.
科学领域:
- 胃肠病学 胃肠病学
- 蛋白质酶信号传递
- 血管生物学 血管生物学
背景情况:
- 蛋白酶越来越多地被认为是它们在肠道功能和疾病中的作用.
- 血红素蛋白酶 - - 血红素蛋白酶 - - 从历史上看,它只与血液静止有关.
- 血受体,蛋白酶激活受体-1和-4 (PAR1,PAR4) 在不同的肠道细胞类型上表达.
研究的目的:
- 审查血栓在肠道生理学的多方面的作用.
- 探索肠道环境中的血栓的调节.
- 讨论血栓素作为肠道疾病的潜在治疗点.
主要方法:
- 关于血素和肠道功能的最近研究的文献综述.
- 对肠道中血栓受体表达和信号的研究进行分析.
- 综合了肠道细胞对构成性血栓释放的发现.
主要成果:
- 血栓激素积极参与肠道屏障,免疫和运动功能.
- 肠上皮细胞构成性地释放活跃的血栓素.
- 凝血素的作用不仅仅是血液静止,还包括肠道平衡.
结论:
- 热血素是肠道生理学和病理生理学的关键调节剂.
- 了解血栓素的肠道功能,可以开辟新的治疗途径.
- 向血栓可能为胃肠道疾病提供新的治疗方法.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
01:16Clot Retraction and Fibrinolysis
5.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.5K
01:24Disorders of Hemostasis
885
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
885
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:09Coagulation
6.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.5K